Chiral effects in adrenocorticolytic action of o,p′-DDD (mitotane) in human adrenal cells

Xenobiotica

Volumn 40, Issue 3, 2010, Pages 177-183

  Asp, V ^a   Cantillana, T ^b   Bergman, A ^b   Brandt, I ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

Adrenocortical cancer (ACC); Chirality; Mitotane; Steroidogenesis

Indexed keywords

HYDROCORTISONE; MITOTANE; PRASTERONE;

ADRENAL CORTEX CELL; ANDROGEN RELEASE; ARTICLE; CELL ASSAY; CELL VIABILITY; CHIRALITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG ISOLATION; DRUG POTENCY; DRUG STRUCTURE; ENANTIOMER; HORMONAL REGULATION; HUMAN; HUMAN CELL; HYDROCORTISONE RELEASE; IC 50; RACEMIC MIXTURE; STRUCTURE ACTIVITY RELATION;

ADRENAL CORTEX; CELL LINE; CELL SURVIVAL; DEHYDROEPIANDROSTERONE; HUMANS; HYDROCORTISONE; MITOTANE; STEREOISOMERISM;

EID: 77149153085     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498250903470230     Document Type: Article

References (30)

1. Ahlman H, Khorram-Manesh A, Jansson S, Wangberg B, Nilsson O, Jacobsson CE, Lindstedt S. (2001). Cytotoxic treatment of adrenocortical carcinoma. World J Surg 25(7):927-933
2. Allolio B, Fassnacht M. (2006). Clinical Review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 91(6):2027-2037
3. Asp V, Lindström V, Olsson JA, Bergström U, Brandt I. (2009). Cytotoxicity and decreased corticosterone production in adrenocortical Y-1 cells by 3-methylsulfonyl-DDE and structurally related molecules. Archiv Toxicol 83(4):389-396
4. Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G, Schlumberger M. (2001). Impact of monitoring plasma 1,1- dichlorodiphenildichloroethane (o,p'-DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92(6): 1385-1392
5. Bergenstal D, Hertz R, Lipsett M, Moy R. (1960). Chemotherapy of adrenocortical cancer with o,p'-DDD. Ann Intern Med 53:672-682
6. Cai W, Benitez R, Counsell RE, Djanegara T, Schteingart DE, Sinsheimer JE, Wotring LL. (1995a). Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p'-DDD] and its p,p'- and m,p'-isomers. Biochem Pharmacol 49(10):1483-1489
7. Cai W, Djanegara T, Sinsheimer J, Wotring L, Counsell E, Schteingart D. (1995b). Metabolic activation and binding of mitotane in adrenal cortex homogenates. J Pharmaceut Sci 84(2):134-138
8. Cantillana T, Eriksson L. (2009). (2S)-1,1-dichloro-2-(2-chlorophenyl)-2- (4-chlorophenyl)ethane. Acta Crystallographica E65:o297.
9. Cantillana T, Lindstrom V, Eriksson L, Brandt I, Bergman A. (2009). Interindividual differences in o,p'-DDD enantiomer kinetics examined in Gottingen minipigs. Chemosphere 76(2):167-172
10. Eriksson T, Björkman S, Höglund P. (2001). Clinical pharmacology of thalidomide. European J Clin Pharmacol 57(5):365-376
11. Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ, Krans HM. (1994). Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69(5):947-951
12. Hahner S, Fassnacht M. (2005). Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 6(4):386-394
13. Hart MM, Reagan RL, Adamson RH. (1973). The effect of isomers of DDD on the ACTH-induced steroid output, histology and ultrastructure of the dog adrenal cortex. Toxicol Appl Pharmacol 24(1):101-113
14. Hart MM, Straw JA. (1971). Studies on the site of action of o,p'-DDD in the dog adrenal cortex. 1. Inhibition of ACTH-mediated pregnenolone synthesis. Steroids 17(1-5):559-574
15. Hart MM, Swackhamer ES, Straw JA. (1971). Studies on the site of action of o,p'-DDD in the dog adrenal cortex. II. TPNH- and corticosteroid precursor-stimulation of o,p'-DDD inhibited steroidogenesis. Steroids 17(1-5):575-586
16. Hoekstra PF, Burnison BK, Neheli T, Muir DC. (2001). Enantiomerspecific activity of o,p'-DDT with the human estrogen receptor. Toxicol Lett 125(1-3):75-81.
17. Huang H, Fojo T. (2008). Adjuvant mitotane for adrenocortical cancer - a recurring controversy. J Clin Endocrinol Metab 93(10):3730-3732
18. Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF, Proye C. (2001). Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 25(7):891-897
19. Lindholm A, Klasson-Wehler E, Wehler T, Bergman Å. (1987). Synthesis of 14C-labelled DDD isomers of high specific activity. J Labelled Comp Radiopharm 24:1011-1019
20. Lund BO, Ghantous H, Bergman Å, Brandt I. (1989). Covalent binding of four DDD isomers in the mouse lung: lack of structure specificity. Pharmacol Toxicol 65(4):282-286
21. Lund BO, Klasson-Wehler E, Brandt I. (1986). o,p'-DDD in the mouse lung: selective uptake, covalent binding and effect on drug metabolism. Chemico-Biol Interact 60(2):129-141
22. Martz F, Straw JA. (1977). The in vitro metabolism of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p'-DDD) by dog adrenal mitochondria and metabolite covalent binding to mitochondrial macromolecules: a possible mechanism for the adrenocorticolytic effect. Drug Metab Dispos 5(5):482-486
23. Martz F, Straw JA. (1980). Metabolism and covalent binding of 1-(ochlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p'-DDD). Correlation between adrenocorticolytic activity and metabolic activation by adrenocortical mitochondria. Drug Metab Dispos 8(3):127-130
24. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. (2006). Cushing's syndrome. Lancet 367(9522):1605-1617
25. Shen H, Virtanen HE, Main KM, Kaleva M, Andersson AM, Skakkebaek NE, Toppari J, Schramm KW. (2006). Enantiomeric ratios as an indicator of exposure processes for persistent pollutants in human placentas. Chemosphere 62(3):390-395
26. Tada H, Shiho O, Kuroshima K, Koyama M, Tsukamoto K. (1986). An improved colorimetric assay for interleukin 2. J Immunol Methods 93(2):157-165
27. Tauchmanova L, Colao A, Marzano LA, Sparano L, Camera L, Rossi A, Palmieri G, Marzano E, Salvatore M, Pettinato G, Rossi R, (2004). Andrenocortical carcinomas: twelve-year prospective experience. World J Surg 28(9):896-903.
28. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker A-C, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A (2007). Adjuvant Mitotane Treatment for Adrenocortical Carcinoma. N Engl J Med 356(23):2372-2380
29. Terzolo M, Berruti A. (2008). Adjunctive treatment of adrenocortical carcinoma. Curr Opin Endocrinol Diabet Obes 15(3):221-226
30. van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D. (1984). The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20(1):47-53.